Se afișează postările cu eticheta Disorders. Afișați toate postările
Se afișează postările cu eticheta Disorders. Afișați toate postările

vineri, 9 decembrie 2011

Dealing With Aggressive Young Offenders With Psychiatric Disorders

Main Category: Psychology / Psychiatry
Also Included In: Mental Health;  Pediatrics / Children's Health
Article Date: 05 Nov 2011 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
4 stars3 stars
Seclusion should always be the last resort when it comes to dealing with aggressive episodes involving young offenders with psychiatric disorders, according to staff who took part in a four-country study published in the November issue of the Journal of Psychiatric and Mental Health Nursing.

Researchers led by the Universities of Turku and Tampere, Finland, report that the multi-disciplinary teams they spoke to said that verbal intervention was their first choice. Putting adolescents in a bare, locked room was viewed as the least favoured option in the three countries where seclusion remains legal.

The research team also found that countries with a longer history of treating adolescents in medium to high security units tended to use less physical restraints on fewer occasions.

"Adolescent aggressive behaviour poses a challenge for staff working in forensic units, which cater for 12 to 18 year-olds who have been in trouble with the law, because it occurs so frequently" says lead author Johanna Berg from the Department of Nursing Science at the University of Turku.

"Our study of units in Belgium, Finland, the Netherlands and UK found that while the principles of dealing with aggression were fairly similar, there were some differences in the practical solutions."

The study comprised forensic units ranging from eight to 12 beds, treating young offenders with a range of problems, including: severe mental health disorders, delinquent, violent and non-compliant behaviour and impulse control problems. One unit was established in the 1980s (UK), two in the 1990s (Belgium and the Netherlands) and one in the 2000s (Finland).

The 58 staff, including nurses, doctors, psychologists, social workers, educators, support workers, occupational, art and family therapists and sports instructors, had an average age of 36.

Key findings from the one-to-one interviews included: Verbal intervention was the favoured technique and was most effective when it was clear, structured and used in the early stages of aggression. Talking about the incident afterwards was also very important, so that both the adolescent and staff could reflect on why it happened and how it could be prevented in future. Staff planned daily routines and worked together so that risks were minimised. Being able to respond quickly and call on colleagues for support, including staff from other units, was vital. Isolation techniques ranged from separating the aggressor from other adolescents for five to 15 minutes, to give them a chance to calm down, to seclusion, which was only used when less restrictive interventions had failed. It was not used in Finland, where it is banned by legislation. Duveting, where the adolescent is swathed in blankets to prevent violent acts and enable staff to transfer them to the seclusion room was not used in the UK unit. Restraint beds with straps were only used in Finland, for intensive care and for as short a time as possible. If medication was needed it was jointly decided between the staff and adolescent, if possible. Forced medication was rarely used and only in major incidents where safety was seriously compromised. Key factors that determined the level of response included the level of aggression involved, how well staff knew the individual adolescent's behaviour and what had proved helpful in the past. Teamwork was important and all members of the multi-disciplinary team needed to be committed to therapeutic aggression management. "Staff in all four units displayed high ethical standards when it came to the use of restrictive treatment measures" says Johanna Berg. "They endeavoured to cooperate with the adolescent as long as possible and avoid coercive measures, while still maintaining the safety of others." The research team have come up with a number of key recommendations for clinical practice as a result of their research: Continuous education is necessary to ensure that staff know how to evaluate incidents and implement the safest and most effective practices when intervening in aggressive situations. Sufficient resources should be available so that the needs of adolescents can be met without compromising the occupation safety and well-being of the staff that care for them. This will help to retain qualified staff in this challenging working environment. Further studies are needed to identify current practices, measure how effective they are and suggest how they could be improved. Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our psychology / psychiatry section for the latest news on this subject. The full paper includes further details of the different approaches employed by the four units, together with quotes from various participants.
Management of aggressive behaviour among adolescents in forensic units: a four-country perspective. Berg et al. Journal of Psychiatric and Mental Health Nursing. 18, pp776-785. (November 2011). doi: 10.1111/j.1365-2850.2011.01726.x
Wiley-Blackwell Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Wiley-Blackwell. "Dealing With Aggressive Young Offenders With Psychiatric Disorders." Medical News Today. MediLexicon, Intl., 5 Nov. 2011. Web.
9 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Early Diagnosis Of Psychotic Disorders

Main Category: Mental Health
Also Included In: Psychology / Psychiatry;  Depression
Article Date: 04 Nov 2011 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
5 stars3 stars
Functional psychosis can be diagnosed from the first indications of the patient, thanks to affective symptomatology. Depressive moods, hyperactivity and lack of concentration are affective symptoms that can present themselves during the first psychotic episodes, and the presence or absence of any of them may contribute to differentiating, at an early stage, between the different variations of the mental disease. Thus concludes researcher Ms Marta Arrasate, who also pointed to the symptoms belonging to the activation dimension (verborrhea, lack of concentration, hyperactivity, etc.) as the best indicators. Her thesis, defended at the UPV/EHU, was entitled Valor predictivo de la sintomatología afectiva en primeros episodios psicóticos (Predictive value of affective symptomatology during the first psychotic episodes).

This is the first European PhD undertaken at the Alava/Araba Unit of the Faculty of Medicine of the UPV/EHU, and was codirected by Ana González-Pinto, 2010 National Award winner of the Spanish Society for Biological Psychiatry. According to Ms González-Pinto, the relevance of the research lies in that "affective symptoms can help not only in telling future prognosis but also in contributing to diagnosis - something difficult in psychiatry because diagnostic tests equivalent to a radiograph, an analysis or a scanner do not exist. This is why, if a test were found, however simple, or rudimentary, it would be of great use".

Evaluation in three stages

Ms Arrasate undertook the study based on a sample of 112 hospitalised patients with a first psychotic episode, and analysed the predictive value of the affective symptoms that present themselves in three concrete moments: initial hospital admission, the third year and the fifth year. In order to evaluate the results, the different affective symptoms were grouped according to dimensions (these classifications being based on a previous study of patients with bipolar disorders), and associated with variables such as the number of relapses, hospital or health centre admissions, suicide attempts, etc.

The results show that the activation dimension (involving symptoms of hyperactivity, lack of concentration and verborrhea, amongst others) can be an especially useful tool for early distinguishing between the various types of psychotic symptoms. This is what has been deduced from the data obtained from a study of one of the principal diseases in this field: bipolar disorder. According to Ms Arrasate's research, the activation and manic dimensions are those which best characterise bipolar disorder. Nevertheless, the manic dimension is absent in the first episodes; moreover, that which is present during these first episodes is the depressive dimension, thus possibly giving rise to confusion and inability in making an early and correct diagnosis. Thus, the results point to the activation dimension as the reliable path to follow: it is a useful predictive factor in the early diagnosis of bipolar disorder with psychotic symptoms.

These results open a new line of research as they prove that affective symptoms are able to discriminate between different psychoses, and contribute to an early diagnosis during its course. In fact, the evaluating panel for Ms Arrasate's thesis have made a point of informing those experts responsible for reviewing diagnostic criteria of mental diseases worldwide of these findings.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mental health section for the latest news on this subject. Marta Arrasate Gil (Bilbao, 1969) is a medical graduate who specialised in psychiatry. She carried out her PhD thesis under the direction of Ms Ana González-Pinto Arrillaga (Head of the Psychiatric Research Service at the Hospital Santiago Apóstol in the Basque Country capital of Vitoria-Gasteiz) and Mr Miguel Gutiérrez Fraile (Head of the Psychiatry Service at the same hospital and Professor of Psychiatry). Both are members of the Department of Neurosciences at the Faculty of Medicine and Odontology (UPV/EHU), where Ms Arrasate defended her thesis. The research was undertaken at the Psychiatric Research Service of the Hospital Santiago Apóstol. Ms Arrasate is currently working at the Psychiatric Service at Basurto Hospital, near the Basque city of Bilbao.
Elhuyar Fundazioa Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Elhuyar Fundazioa. "Early Diagnosis Of Psychotic Disorders." Medical News Today. MediLexicon, Intl., 4 Nov. 2011. Web.
9 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Reducing The Treatment Gap For Mental, Neurological, And Substance Use Disorders

Main Category: Mental Health
Also Included In: Neurology / Neuroscience;  Alcohol / Addiction / Illegal Drugs
Article Date: 17 Nov 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
In this week's PLoS Medicine, Shekhar Saxena of the WHO in Geneva, Switzerland and colleagues summarize the recent WHO Mental Health Gap Action Programme (mhGAP) intervention guide that provides evidence-based management recommendations for mental, neurological, and substance use (MNS) disorders.

This guide is aimed at reducing the treatment gap for MNS disorders, which is more than 75% in many low- and middle-income countries (LMICs). Further details and background material to the guide can be accessed on the WHO website: http://bit.ly/vKPSRF

The authors recommend that: "In the near future, further efforts should be made to introduce formal evaluations of the capability of [treatment] programs to induce relevant and persistent changes, and to generate useful insights on how implementation in [low- and middle-income countries] should be conducted to maximize benefit at sustainable costs."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mental health section for the latest news on this subject. The PLoS Medicine Mental Health in Low- and Middle-Income Countries Collection, a seven-part series of articles published between October 2009 and February 2010, provides further information on mental, neurological, and substance-use disorders in LMICs.
Funding: Funding for the mhGAP Programme, under which the work reported in this manuscript was done, was provided by the following: American Psychiatric Foundation, USA; Association of Aichi Psychiatric Hospitals, Japan; Autism Speaks, USA; CBM; Government of Italy; Government of Japan; Government of The Netherlands; International Bureau for Epilepsy; International League Against Epilepsy; Medical Research Council, UK; National Institute of Mental Health, USA; Public Health Agency of Canada, Canada; Rockefeller Foundation, USA; Shirley Foundation, UK; Syngenta, Switzerland; United Nations Population Fund;World Psychiatric Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JLA was paid in 2007 by Lundbeck S.A. for consultancy preparation of the research protocol for a study on the diagnostic delay in first episode of depression in contact with health care centers in Spain and was paid in 2009 by Sanofi Aventis S.A. for expert testimony on the side effects of veralapride. OO is the current President of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) (http://www.iacapap.org/). JWS served on scientific advisory boards for GlaxoSmithKline (2010), Eisai (2009), and UCB (2009); received funding for travel from UCB (2008) and Janssen (2009); serves on the editorial boards of Lancet Neurology, Epilepsia and Epileptic Disorders; served on the speaker's bureaus of UCB (2009) and GlaxoSmithKline (2009); and has received research support from UCB (grant finished 2010), Eisai (grant finished 2008), the NIH (ongoing grant), the EU FP7 (ongoing grant), the Wellcome Trust (grant finished 2009), WHO (ongoing grant), the National Epilepsy Funds of the Netherlands (ongoing grant), and the Epilepsy Society (ongoing grant). His current position is endowed by the National Society for Epilepsy (UK). SS confirms that the competing interests of JWS were declared, reviewed, and deemed acceptable by the mhGAP Guideline Development Group. All other authors have declared that no competing interests exist.
Citation: Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, et al. (2011) Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations. PLoS Med 8(11): e1001122. doi:10.1371/journal.pmed.1001122
Public Library of Science Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Public Library of Science. "Reducing The Treatment Gap For Mental, Neurological, And Substance Use Disorders." Medical News Today. MediLexicon, Intl., 17 Nov. 2011. Web.
9 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Healthy Minds Initiative Launched To Encourage Neuroscience Collaboration And Support Those With Brain Disorders

Editor's Choice
Main Category: Mental Health
Also Included In: Psychology / Psychiatry
Article Date: 13 Nov 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
5 stars4 stars
Millions of people worldwide are affected by brain disorders. Janssen Pharmaceutical Inc. ("Janssen") announced the launch of a comprehensive initiative called Healthy Minds to speed up progress in the fight against brain disorders. Janssen Pharmaceuticals Inc. is making a substantial new commitment of $3 million in direct and challenge contributions to the International Mental Health Research Organization (IMHRO), a nonprofit organization that aims to improve people's health and functioning for those suffering from brain or central nervous system disorders. IMHORO supports One Mind for Research, an IMHRO program supporting neuroscience research, education, and awareness-building programs, that was started by former U.S. Congressman Patrick Kennedy and Garen Staglin, Vice President, Board of Directors, IMHRO.

Through their new initiative, Janssen will become the first private-sector partner to support the One Mind for Research program with $2 million contributions in cash to IMHRO and $1 million in matching funds for donations raised by IMHRO for the One Mind for Research program from other private-sector partners. The program aims to create collaborative neuroscience networks and data-sharing programs enhancing basic discovery and speeding clinical translation.

Janssen intends to take on an active role in the program, by developing research programs, increase data sharing amongst scientists and physicians who focus on the brain or central nervous system, and to improve and better understand the molecular and cellular origins of mental and neurological disorders, thus helping to tackle the stigma attached for people affected by brain diseases.

One Mind for Research's target is to de-stigmatize mental-health conditions and gain a better understanding of their molecular and cellular origins, whilst Healthy Minds seeks to encourage collaboration among biotechnology, pharmaceutical, and public-sector partners to speed up the discovery of new therapeutic solutions for brain disease.

Sheri McCoy, Vice Chairman, Executive Committee, Johnson & Johnson explains:

"Brain disorders are one of the most challenging areas of scientific research. Despite great progress in advancing new treatments, the brain remains a medical mystery and millions of people continue to suffer from Alzheimer's disease, depression, post traumatic stress disorder, neurological conditions, and many other debilitating and life threatening brain diseases."

Husseini K. Manji, M.D., Global Therapeutic Area Head for Neuroscience, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. adds:

"Rapid advances in science and technology over the past decade provide us with an unprecedented opportunity and the tools needed to unlock the secrets of the brain, but the challenge is too great and the data too vast for any one entity to do it alone. A concerted and focused effort, including public-private partnerships, is needed to foster the development of new, transformational medicines and treatment paradigms.

Building on our heritage and capabilities in neuroscience and our culture of networked innovation, we are proud of the Healthy Minds initiative. We are pleased to support the One Mind for Research efforts to get to the next frontier of neuroscience and support improved health of millions of people who suffer from brain disorders."

Healthy Minds is built on Janssen's longstanding experience dating back to the 1950s as well as the company's achievement in advancing neuroscience research, such as Dr. Paul Janssen's discovery and development of one of the first breakthrough treatments for schizophrenia. Dr Janssen, after whom the company is named, established himself as one of the 20th century's most talented and passionate physicians and pharmaceutical researchers. He remains strongly committed to neuroscience and has since discovered, developed and launched numerous new treatments for brain and central nervous system conditions. Each year, Janssen commits over $12 million to causes regarding brain disorders and mental illness, such as public and professional education, sponsorships and philanthropy in neuroscience and mental health. The company's contribution to IMHRO underlines Janssen's ongoing commitment in neuroscience research and development.

Former U.S. Congressman Patrick Kennedy declared:

"Janssen is leading the way with its partnerships in developing scientific and public health solutions in the fight against brain disorders. We are pleased to welcome them as a key private-sector partner in driving forward important R&D and awareness-building initiatives. This support will lead to a fundamental understanding of the human brain, what causes brain disorders, and how they can be treated and cured."

Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our mental health section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Petra Rattue. "Healthy Minds Initiative Launched To Encourage Neuroscience Collaboration And Support Those With Brain Disorders." Medical News Today. MediLexicon, Intl., 13 Nov. 2011. Web.
9 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

joi, 8 decembrie 2011

Healthy Minds Initiative Launched To Encourage Neuroscience Collaboration And Support Those With Brain Disorders

Editor's Choice
Main Category: Mental Health
Also Included In: Psychology / Psychiatry
Article Date: 13 Nov 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
5 stars4 stars
Millions of people worldwide are affected by brain disorders. Janssen Pharmaceutical Inc. ("Janssen") announced the launch of a comprehensive initiative called Healthy Minds to speed up progress in the fight against brain disorders. Janssen Pharmaceuticals Inc. is making a substantial new commitment of $3 million in direct and challenge contributions to the International Mental Health Research Organization (IMHRO), a nonprofit organization that aims to improve people's health and functioning for those suffering from brain or central nervous system disorders. IMHORO supports One Mind for Research, an IMHRO program supporting neuroscience research, education, and awareness-building programs, that was started by former U.S. Congressman Patrick Kennedy and Garen Staglin, Vice President, Board of Directors, IMHRO.

Through their new initiative, Janssen will become the first private-sector partner to support the One Mind for Research program with $2 million contributions in cash to IMHRO and $1 million in matching funds for donations raised by IMHRO for the One Mind for Research program from other private-sector partners. The program aims to create collaborative neuroscience networks and data-sharing programs enhancing basic discovery and speeding clinical translation.

Janssen intends to take on an active role in the program, by developing research programs, increase data sharing amongst scientists and physicians who focus on the brain or central nervous system, and to improve and better understand the molecular and cellular origins of mental and neurological disorders, thus helping to tackle the stigma attached for people affected by brain diseases.

One Mind for Research's target is to de-stigmatize mental-health conditions and gain a better understanding of their molecular and cellular origins, whilst Healthy Minds seeks to encourage collaboration among biotechnology, pharmaceutical, and public-sector partners to speed up the discovery of new therapeutic solutions for brain disease.

Sheri McCoy, Vice Chairman, Executive Committee, Johnson & Johnson explains:

"Brain disorders are one of the most challenging areas of scientific research. Despite great progress in advancing new treatments, the brain remains a medical mystery and millions of people continue to suffer from Alzheimer's disease, depression, post traumatic stress disorder, neurological conditions, and many other debilitating and life threatening brain diseases."

Husseini K. Manji, M.D., Global Therapeutic Area Head for Neuroscience, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. adds:

"Rapid advances in science and technology over the past decade provide us with an unprecedented opportunity and the tools needed to unlock the secrets of the brain, but the challenge is too great and the data too vast for any one entity to do it alone. A concerted and focused effort, including public-private partnerships, is needed to foster the development of new, transformational medicines and treatment paradigms.

Building on our heritage and capabilities in neuroscience and our culture of networked innovation, we are proud of the Healthy Minds initiative. We are pleased to support the One Mind for Research efforts to get to the next frontier of neuroscience and support improved health of millions of people who suffer from brain disorders."

Healthy Minds is built on Janssen's longstanding experience dating back to the 1950s as well as the company's achievement in advancing neuroscience research, such as Dr. Paul Janssen's discovery and development of one of the first breakthrough treatments for schizophrenia. Dr Janssen, after whom the company is named, established himself as one of the 20th century's most talented and passionate physicians and pharmaceutical researchers. He remains strongly committed to neuroscience and has since discovered, developed and launched numerous new treatments for brain and central nervous system conditions. Each year, Janssen commits over $12 million to causes regarding brain disorders and mental illness, such as public and professional education, sponsorships and philanthropy in neuroscience and mental health. The company's contribution to IMHRO underlines Janssen's ongoing commitment in neuroscience research and development.

Former U.S. Congressman Patrick Kennedy declared:

"Janssen is leading the way with its partnerships in developing scientific and public health solutions in the fight against brain disorders. We are pleased to welcome them as a key private-sector partner in driving forward important R&D and awareness-building initiatives. This support will lead to a fundamental understanding of the human brain, what causes brain disorders, and how they can be treated and cured."

Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our mental health section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Petra Rattue. "Healthy Minds Initiative Launched To Encourage Neuroscience Collaboration And Support Those With Brain Disorders." Medical News Today. MediLexicon, Intl., 13 Nov. 2011. Web.
8 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Early Diagnosis Of Psychotic Disorders

Main Category: Mental Health
Also Included In: Psychology / Psychiatry;  Depression
Article Date: 04 Nov 2011 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
5 stars3 stars
Functional psychosis can be diagnosed from the first indications of the patient, thanks to affective symptomatology. Depressive moods, hyperactivity and lack of concentration are affective symptoms that can present themselves during the first psychotic episodes, and the presence or absence of any of them may contribute to differentiating, at an early stage, between the different variations of the mental disease. Thus concludes researcher Ms Marta Arrasate, who also pointed to the symptoms belonging to the activation dimension (verborrhea, lack of concentration, hyperactivity, etc.) as the best indicators. Her thesis, defended at the UPV/EHU, was entitled Valor predictivo de la sintomatología afectiva en primeros episodios psicóticos (Predictive value of affective symptomatology during the first psychotic episodes).

This is the first European PhD undertaken at the Alava/Araba Unit of the Faculty of Medicine of the UPV/EHU, and was codirected by Ana González-Pinto, 2010 National Award winner of the Spanish Society for Biological Psychiatry. According to Ms González-Pinto, the relevance of the research lies in that "affective symptoms can help not only in telling future prognosis but also in contributing to diagnosis - something difficult in psychiatry because diagnostic tests equivalent to a radiograph, an analysis or a scanner do not exist. This is why, if a test were found, however simple, or rudimentary, it would be of great use".

Evaluation in three stages

Ms Arrasate undertook the study based on a sample of 112 hospitalised patients with a first psychotic episode, and analysed the predictive value of the affective symptoms that present themselves in three concrete moments: initial hospital admission, the third year and the fifth year. In order to evaluate the results, the different affective symptoms were grouped according to dimensions (these classifications being based on a previous study of patients with bipolar disorders), and associated with variables such as the number of relapses, hospital or health centre admissions, suicide attempts, etc.

The results show that the activation dimension (involving symptoms of hyperactivity, lack of concentration and verborrhea, amongst others) can be an especially useful tool for early distinguishing between the various types of psychotic symptoms. This is what has been deduced from the data obtained from a study of one of the principal diseases in this field: bipolar disorder. According to Ms Arrasate's research, the activation and manic dimensions are those which best characterise bipolar disorder. Nevertheless, the manic dimension is absent in the first episodes; moreover, that which is present during these first episodes is the depressive dimension, thus possibly giving rise to confusion and inability in making an early and correct diagnosis. Thus, the results point to the activation dimension as the reliable path to follow: it is a useful predictive factor in the early diagnosis of bipolar disorder with psychotic symptoms.

These results open a new line of research as they prove that affective symptoms are able to discriminate between different psychoses, and contribute to an early diagnosis during its course. In fact, the evaluating panel for Ms Arrasate's thesis have made a point of informing those experts responsible for reviewing diagnostic criteria of mental diseases worldwide of these findings.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mental health section for the latest news on this subject. Marta Arrasate Gil (Bilbao, 1969) is a medical graduate who specialised in psychiatry. She carried out her PhD thesis under the direction of Ms Ana González-Pinto Arrillaga (Head of the Psychiatric Research Service at the Hospital Santiago Apóstol in the Basque Country capital of Vitoria-Gasteiz) and Mr Miguel Gutiérrez Fraile (Head of the Psychiatry Service at the same hospital and Professor of Psychiatry). Both are members of the Department of Neurosciences at the Faculty of Medicine and Odontology (UPV/EHU), where Ms Arrasate defended her thesis. The research was undertaken at the Psychiatric Research Service of the Hospital Santiago Apóstol. Ms Arrasate is currently working at the Psychiatric Service at Basurto Hospital, near the Basque city of Bilbao.
Elhuyar Fundazioa Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Elhuyar Fundazioa. "Early Diagnosis Of Psychotic Disorders." Medical News Today. MediLexicon, Intl., 4 Nov. 2011. Web.
8 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Reducing The Treatment Gap For Mental, Neurological, And Substance Use Disorders

Main Category: Mental Health
Also Included In: Neurology / Neuroscience;  Alcohol / Addiction / Illegal Drugs
Article Date: 17 Nov 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
In this week's PLoS Medicine, Shekhar Saxena of the WHO in Geneva, Switzerland and colleagues summarize the recent WHO Mental Health Gap Action Programme (mhGAP) intervention guide that provides evidence-based management recommendations for mental, neurological, and substance use (MNS) disorders.

This guide is aimed at reducing the treatment gap for MNS disorders, which is more than 75% in many low- and middle-income countries (LMICs). Further details and background material to the guide can be accessed on the WHO website: http://bit.ly/vKPSRF

The authors recommend that: "In the near future, further efforts should be made to introduce formal evaluations of the capability of [treatment] programs to induce relevant and persistent changes, and to generate useful insights on how implementation in [low- and middle-income countries] should be conducted to maximize benefit at sustainable costs."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mental health section for the latest news on this subject. The PLoS Medicine Mental Health in Low- and Middle-Income Countries Collection, a seven-part series of articles published between October 2009 and February 2010, provides further information on mental, neurological, and substance-use disorders in LMICs.
Funding: Funding for the mhGAP Programme, under which the work reported in this manuscript was done, was provided by the following: American Psychiatric Foundation, USA; Association of Aichi Psychiatric Hospitals, Japan; Autism Speaks, USA; CBM; Government of Italy; Government of Japan; Government of The Netherlands; International Bureau for Epilepsy; International League Against Epilepsy; Medical Research Council, UK; National Institute of Mental Health, USA; Public Health Agency of Canada, Canada; Rockefeller Foundation, USA; Shirley Foundation, UK; Syngenta, Switzerland; United Nations Population Fund;World Psychiatric Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JLA was paid in 2007 by Lundbeck S.A. for consultancy preparation of the research protocol for a study on the diagnostic delay in first episode of depression in contact with health care centers in Spain and was paid in 2009 by Sanofi Aventis S.A. for expert testimony on the side effects of veralapride. OO is the current President of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) (http://www.iacapap.org/). JWS served on scientific advisory boards for GlaxoSmithKline (2010), Eisai (2009), and UCB (2009); received funding for travel from UCB (2008) and Janssen (2009); serves on the editorial boards of Lancet Neurology, Epilepsia and Epileptic Disorders; served on the speaker's bureaus of UCB (2009) and GlaxoSmithKline (2009); and has received research support from UCB (grant finished 2010), Eisai (grant finished 2008), the NIH (ongoing grant), the EU FP7 (ongoing grant), the Wellcome Trust (grant finished 2009), WHO (ongoing grant), the National Epilepsy Funds of the Netherlands (ongoing grant), and the Epilepsy Society (ongoing grant). His current position is endowed by the National Society for Epilepsy (UK). SS confirms that the competing interests of JWS were declared, reviewed, and deemed acceptable by the mhGAP Guideline Development Group. All other authors have declared that no competing interests exist.
Citation: Dua T, Barbui C, Clark N, Fleischmann A, Poznyak V, et al. (2011) Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations. PLoS Med 8(11): e1001122. doi:10.1371/journal.pmed.1001122
Public Library of Science Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Public Library of Science. "Reducing The Treatment Gap For Mental, Neurological, And Substance Use Disorders." Medical News Today. MediLexicon, Intl., 17 Nov. 2011. Web.
8 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Dealing With Aggressive Young Offenders With Psychiatric Disorders

Main Category: Psychology / Psychiatry
Also Included In: Mental Health;  Pediatrics / Children's Health
Article Date: 05 Nov 2011 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
4 stars3 stars
Seclusion should always be the last resort when it comes to dealing with aggressive episodes involving young offenders with psychiatric disorders, according to staff who took part in a four-country study published in the November issue of the Journal of Psychiatric and Mental Health Nursing.

Researchers led by the Universities of Turku and Tampere, Finland, report that the multi-disciplinary teams they spoke to said that verbal intervention was their first choice. Putting adolescents in a bare, locked room was viewed as the least favoured option in the three countries where seclusion remains legal.

The research team also found that countries with a longer history of treating adolescents in medium to high security units tended to use less physical restraints on fewer occasions.

"Adolescent aggressive behaviour poses a challenge for staff working in forensic units, which cater for 12 to 18 year-olds who have been in trouble with the law, because it occurs so frequently" says lead author Johanna Berg from the Department of Nursing Science at the University of Turku.

"Our study of units in Belgium, Finland, the Netherlands and UK found that while the principles of dealing with aggression were fairly similar, there were some differences in the practical solutions."

The study comprised forensic units ranging from eight to 12 beds, treating young offenders with a range of problems, including: severe mental health disorders, delinquent, violent and non-compliant behaviour and impulse control problems. One unit was established in the 1980s (UK), two in the 1990s (Belgium and the Netherlands) and one in the 2000s (Finland).

The 58 staff, including nurses, doctors, psychologists, social workers, educators, support workers, occupational, art and family therapists and sports instructors, had an average age of 36.

Key findings from the one-to-one interviews included: Verbal intervention was the favoured technique and was most effective when it was clear, structured and used in the early stages of aggression. Talking about the incident afterwards was also very important, so that both the adolescent and staff could reflect on why it happened and how it could be prevented in future. Staff planned daily routines and worked together so that risks were minimised. Being able to respond quickly and call on colleagues for support, including staff from other units, was vital. Isolation techniques ranged from separating the aggressor from other adolescents for five to 15 minutes, to give them a chance to calm down, to seclusion, which was only used when less restrictive interventions had failed. It was not used in Finland, where it is banned by legislation. Duveting, where the adolescent is swathed in blankets to prevent violent acts and enable staff to transfer them to the seclusion room was not used in the UK unit. Restraint beds with straps were only used in Finland, for intensive care and for as short a time as possible. If medication was needed it was jointly decided between the staff and adolescent, if possible. Forced medication was rarely used and only in major incidents where safety was seriously compromised. Key factors that determined the level of response included the level of aggression involved, how well staff knew the individual adolescent's behaviour and what had proved helpful in the past. Teamwork was important and all members of the multi-disciplinary team needed to be committed to therapeutic aggression management. "Staff in all four units displayed high ethical standards when it came to the use of restrictive treatment measures" says Johanna Berg. "They endeavoured to cooperate with the adolescent as long as possible and avoid coercive measures, while still maintaining the safety of others." The research team have come up with a number of key recommendations for clinical practice as a result of their research: Continuous education is necessary to ensure that staff know how to evaluate incidents and implement the safest and most effective practices when intervening in aggressive situations. Sufficient resources should be available so that the needs of adolescents can be met without compromising the occupation safety and well-being of the staff that care for them. This will help to retain qualified staff in this challenging working environment. Further studies are needed to identify current practices, measure how effective they are and suggest how they could be improved. Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our psychology / psychiatry section for the latest news on this subject. The full paper includes further details of the different approaches employed by the four units, together with quotes from various participants.
Management of aggressive behaviour among adolescents in forensic units: a four-country perspective. Berg et al. Journal of Psychiatric and Mental Health Nursing. 18, pp776-785. (November 2011). doi: 10.1111/j.1365-2850.2011.01726.x
Wiley-Blackwell Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Wiley-Blackwell. "Dealing With Aggressive Young Offenders With Psychiatric Disorders." Medical News Today. MediLexicon, Intl., 5 Nov. 2011. Web.
8 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here